Haleon to invest $54 mln in US R&D centre to ... invest $54 million in its global research and development centre in Richmond, U.S., aiming to boost its pipeline for new product innovations.

(Sharecast News) - Haleon announced on Tuesday that it has agreed to acquire the remaining 12% stake in its Chinese over-the-counter joint venture, Tianjin TSKF Pharmaceutical, for CNY 1.623bn ...

Haleon entered into an agreement to fully acquire Chinese joint venture Tianjin TSKF Pharmaceuticals in a deal valued at 200 million pounds ($263.8 million), lifting its stake to 100% from 88% ...

March 19 (Reuters) - Drugmaker Pfizer (PFE.N), opens new tab has sold its entire stake in Haleon (HLN.L), opens new tab for about 2.5 billion pounds ($3.24 billion) to institutional investors and ...

As a hybrid healthcare and consumer staple stock, Haleon offers plenty of stability amidst the current market volatility, with its Power Brands driving strong organic growth. Room for expanding ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Pfizer sold its remaining 7.3% stake in Haleon for $3.1 billion, fully exiting its position in the company. Haleon expects 2025 organic revenue growth of 4% to 6%, with stronger performance in the ...

(Reuters) -Pfizer will sell its remaining stake in British consumer healthcare group Haleon, the companies said on Tuesday. Pfizer will sell about 662 million ordinary shares, or 7.3%, of Haleon ...

(Bloomberg) -- Pfizer Inc. raised about £2.55 billion ($3.3 billion) through the sale of its remaining 7.3% stake in Haleon Plc, culminating a years-long separation from the maker of Sensodyne ...

Pfizer Inc. (PFE) agreed to sell its remaining stake worth $3.3 billion in Haleon PLC (HLN), marking its exit from the UK-based consumer healthcare company. The American pharma giant announced on ...